Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Genentech
(https://kadcyla.com) 📸 Data Snapshot: May 31, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE KADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast Cancer (https://kadcyla.com)
Title
KADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast Cancer
Meta
Learn about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with early or metastatic HER2+ breast cancer. See Full Safety and Boxed Warnings for more information.
H1 What will your treatment journey look like?
H2 What is the most Important Safety Information I should know about KADCYLA?
H2 What are the additional possible serious side effects of KADCYLA?
H2 What are the most common side effects of KADCYLA?
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 Important Safety Information/Uses
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
HEADING_REPEATED_BODY Early Breast Cancer | KADCYLA® (ado-trastuzumab emtansine) (https://kadcyla.com/early-breast-cancer.html)
Title
Early Breast Cancer | KADCYLA® (ado-trastuzumab emtansine)
Meta
Read about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information.
H1 2 cancer-fighting agents in 1 drug
H2 Financial support options
H2 Starting the conversation
H2 Taking KADCYLA
H2 What is the most Important Safety Information I should know about KADCYLA?
H2 What are the additional possible serious side effects of KADCYLA?
H2 What are the most common side effects of KADCYLA?
H3 Financial support options
H3 Starting the conversation
H3 Taking KADCYLA
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 Important Safety Information/Uses
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
HEADING_REPEATED_BODY Metastatic Breast Cancer | KADCYLA® (ado-trastuzumab emtansine) (https://kadcyla.com/metastatic-breast-cancer.html)
Title
Metastatic Breast Cancer | KADCYLA® (ado-trastuzumab emtansine)
Meta
Read about KADCYLA® for certain patients with HER2+ metastatic breast cancer. See Full Safety and Boxed Warnings for more information.
H1 2 cancer-fighting agents in 1 drug
H2 Financial support options
H2 Starting the conversation
H2 Taking KADCYLA
H2 What is the most Important Safety Information I should know about KADCYLA?
H2 What are the additional possible serious side effects of KADCYLA?
H2 What are the most common side effects of KADCYLA?
H3 Financial support options
H3 Starting the conversation
H3 Taking KADCYLA
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 Important Safety Information/Uses
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_REPEATED KADCYLA® (ado-trastuzumab emtansine) Important Safety Information (https://kadcyla.com/safety.html)
Title
KADCYLA® (ado-trastuzumab emtansine) Important Safety Information
Meta
See the full KADCYLA® important Safety Information and Boxed Warnings for more information.
H1 KADCYLA Uses and Important Safety Information
H2 What is the most Important Safety Information I should know about KADCYLA?
H2 What are the additional possible serious side effects of KADCYLA?
H2 What are the most common side effects of KADCYLA?
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://kadcyla.com) KADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast Cancer
[H1] What will your treatment journey look like? KADCYLA can play a role in treating HER2+ early breast cancer or HER2+ metastatic breast cancer. Learn about KADCYLA for early breast cancer Learn about KADCYLA for metastatic breast cancer [H1] What will your treatment journey look like? KADCYLA can play a role in treating HER2+ early breast cancer or HER2+ metastatic breast cancer. Learn about KADCYLA for early breast cancer Learn about KADCYLA for metastatic breast cancer [H4] Important Safety Information/Uses Back to Top [H1] Who is KADCYLA for? Early Breast Cancer KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA. Metastatic Breast Cancer KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body. Patients are selected for therapy based on an FDA-approved test for KADCYLA. [H1] Important Safety Information [H2] What is the most Important Safety Information I should know about KADCYLA? Liver problems KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching Heart problems KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness, or irregular heartbeat Pregnancy Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 7 months after your last dose of KADCYLA If you think you may be pregnant, you should contact your healthcare provider immediately If you are exposed to KADCYLA during pregnancy or if you become pregnant within 7 months following your last dose of KADCYLA, you are encouraged to report KADCYLA exposure to Genentech by calling 1-888-835-2555 If you are a male patient with a female partner that could become pregnant, birth control should be used during treatment and for 4 months following your last dose of KADCYLA You should not breastfeed during treatment and for 7 months after the last dose of KADCYLA Contact your doctor right away if you experience symptoms associated with these side effects. [H2] What are the additional possible serious side effects of KADCYLA? Lung problems KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs Infusion-related reactions Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions Serious bleeding KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood (antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide additional monitoring if you are taking one of these other drugs while on KADCYLA. Even when blood thinners are not also being taken, life-threatening bleeding may occur with KADCYLA Low platelet count Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms Nerve damage Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function. Your doctor will monitor you for symptoms of nerve damage Skin reactions around the infusion site KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion [H2] What are the most common side effects of KADCYLA? The most common side effects in people taking KADCYLA for early breast cancer are: Tiredness Nausea Liver problems Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Weakness, numbness, and pain in the hands and feet Joint pain The most common side effects seen in people taking KADCYLA for metastatic breast cancer are: Tiredness Nausea Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Liver problems Constipation Nosebleeds You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. Talk to a healthcare professional for more information about the benefits and risks of KADCYLA. Please see full Prescribing Information for Important Safety Information, including most serious side effects. If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows lymph nodes to which breast cancer can spread, such as those around or near the collarbone, in the armpits, and near the breastbone. Overview This image shows what your treatment plan may look like. Details Diagnosis Neoadjuvant treatment Surgery Adjuvant treatment If SOME cancer cells are present in the tissue removed (known as residual disease), you may start on KADCYLA If NO cancer cells are present in the tissue removed, you do not have residual disease. KADCYLA is not approved for this use, but you may receive other treatment options. Overview This image provides information about neoadjuvant and adjuvant treatment. Details Neoadjuvant treatment (before surgery) One of the goals of neoadjuvant treatment is to help reduce or get rid of cancer cells before surgery. Adjuvant treatment (after surgery) Adjuvant treatment is given with the intent to kill any cancer cells left behind after surgery. Overview This image shows what happened three years after people started the study. Details Three years after people started the study: Eighty-eight percent of the 743 people who received KADCYLA were still cancer free, compared to 77% of the 743 people who received Herceptin The chance of cancer coming back was lowered by 50% for people who received KADCYLA compared to people who received Herceptin At this time of this data review, it was too early in the study to determine if people lived longer with KADCYLA. However, people in the study will continue to be followed and evaluated. This image shows that 1 infusion of KADCYLA is given every 3 weeks for 14 cycles. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows that 1 infusion of KADCYLA is given every 3 weeks. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions.
9323 chars
SUB-PAGE (https://kadcyla.com/early-breast-cancer.html) Early Breast Cancer | KADCYLA® (ado-trastuzumab emtansine)
For eligible patients with HER2+ early breast cancer [H1] 2 cancer-fighting agents in 1 drug With KADCYLA, you receive both a HER2-targeted treatment and a chemotherapy at the same time Learn more For eligible patients with HER2+ early breast cancer [H1] 2 cancer-fighting agents in 1 drug With KADCYLA, you receive both a HER2-targeted treatment and a chemotherapy at the same time Learn more [IMG: Financial support] [H2] Financial support options If you need help paying for KADCYLA, there may be options to help. See what’s available [IMG: Conversation] [H2] Starting the conversation Questions to ask your doctor before and during treatment with KADCYLA. Get started [IMG: Treatment] [H2] Taking KADCYLA Understand how KADCYLA is given for early breast cancer. What to expect [H4] Important Safety Information/Uses Back to Top [H1] Who is KADCYLA for? Early Breast Cancer KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA. Metastatic Breast Cancer KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body. Patients are selected for therapy based on an FDA-approved test for KADCYLA. [H1] Important Safety Information [H2] What is the most Important Safety Information I should know about KADCYLA? Liver problems KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching Heart problems KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness, or irregular heartbeat Pregnancy Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 7 months after your last dose of KADCYLA If you think you may be pregnant, you should contact your healthcare provider immediately If you are exposed to KADCYLA during pregnancy or if you become pregnant within 7 months following your last dose of KADCYLA, you are encouraged to report KADCYLA exposure to Genentech by calling 1-888-835-2555 If you are a male patient with a female partner that could become pregnant, birth control should be used during treatment and for 4 months following your last dose of KADCYLA You should not breastfeed during treatment and for 7 months after the last dose of KADCYLA Contact your doctor right away if you experience symptoms associated with these side effects. [H2] What are the additional possible serious side effects of KADCYLA? Lung problems KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs Infusion-related reactions Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions Serious bleeding KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood (antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide additional monitoring if you are taking one of these other drugs while on KADCYLA. Even when blood thinners are not also being taken, life-threatening bleeding may occur with KADCYLA Low platelet count Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms Nerve damage Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function. Your doctor will monitor you for symptoms of nerve damage Skin reactions around the infusion site KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion [H2] What are the most common side effects of KADCYLA? The most common side effects in people taking KADCYLA for early breast cancer are: Tiredness Nausea Liver problems Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Weakness, numbness, and pain in the hands and feet Joint pain The most common side effects seen in people taking KADCYLA for metastatic breast cancer are: Tiredness Nausea Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Liver problems Constipation Nosebleeds You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. Talk to a healthcare professional for more information about the benefits and risks of KADCYLA. Please see full Prescribing Information for Important Safety Information, including most serious side effects. If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows lymph nodes to which breast cancer can spread, such as those around or near the collarbone, in the armpits, and near the breastbone. Overview This image shows what your treatment plan may look like. Details Diagnosis Neoadjuvant treatment Surgery Adjuvant treatment If SOME cancer cells are present in the tissue removed (known as residual disease), you may start on KADCYLA If NO cancer cells are present in the tissue removed, you do not have residual disease. KADCYLA is not approved for this use, but you may receive other treatment options. Overview This image provides information about neoadjuvant and adjuvant treatment. Details Neoadjuvant treatment (before surgery) One of the goals of neoadjuvant treatment is to help reduce or get rid of cancer cells before surgery. Adjuvant treatment (after surgery) Adjuvant treatment is given with the intent to kill any cancer cells left behind after surgery. Overview This image shows what happened three years after people started the study. Details Three years after people started the study: Eighty-eight percent of the 743 people who received KADCYLA were still cancer free, compared to 77% of the 743 people who received Herceptin The chance of cancer coming back was lowered by 50% for people who received KADCYLA compared to people who received Herceptin At this time of this data review, it was too early in the study to determine if people lived longer with KADCYLA. However, people in the study will continue to be followed and evaluated. This image shows that 1 infusion of KADCYLA is given every 3 weeks for 14 cycles. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows that 1 infusion of KADCYLA is given every 3 weeks. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions.
9683 chars
SUB-PAGE (https://kadcyla.com/metastatic-breast-cancer.html) Metastatic Breast Cancer | KADCYLA® (ado-trastuzumab emtansine)
For patients with previously treated HER2+ metastatic breast cancer [H1] 2 cancer-fighting agents in 1 drug with KADCYLA, you receive both a HER2-targeted treatment and a chemotherapy at the same time. Learn more For patients with previously treated HER2+ metastatic breast cancer [H1] 2 cancer-fighting agents in 1 drug with KADCYLA, you receive both a HER2-targeted treatment and a chemotherapy at the same time. Learn more [IMG: Financial support] [H2] Financial support options If you need help paying for KADCYLA, there may be options to help. See what’s available [IMG: Conversation] [H2] Starting the conversation Questions to ask your doctor before and during treatment with KADCYLA. Get started [IMG: Treatment] [H2] Taking KADCYLA Understand how KADCYLA is given for metastatic breast cancer. What to expect [H4] Important Safety Information/Uses Back to Top [H1] Who is KADCYLA for? Early Breast Cancer KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA. Metastatic Breast Cancer KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body. Patients are selected for therapy based on an FDA-approved test for KADCYLA. [H1] Important Safety Information [H2] What is the most Important Safety Information I should know about KADCYLA? Liver problems KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching Heart problems KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness, or irregular heartbeat Pregnancy Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 7 months after your last dose of KADCYLA If you think you may be pregnant, you should contact your healthcare provider immediately If you are exposed to KADCYLA during pregnancy or if you become pregnant within 7 months following your last dose of KADCYLA, you are encouraged to report KADCYLA exposure to Genentech by calling 1-888-835-2555 If you are a male patient with a female partner that could become pregnant, birth control should be used during treatment and for 4 months following your last dose of KADCYLA You should not breastfeed during treatment and for 7 months after the last dose of KADCYLA Contact your doctor right away if you experience symptoms associated with these side effects. [H2] What are the additional possible serious side effects of KADCYLA? Lung problems KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs Infusion-related reactions Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions Serious bleeding KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood (antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide additional monitoring if you are taking one of these other drugs while on KADCYLA. Even when blood thinners are not also being taken, life-threatening bleeding may occur with KADCYLA Low platelet count Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms Nerve damage Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function. Your doctor will monitor you for symptoms of nerve damage Skin reactions around the infusion site KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion [H2] What are the most common side effects of KADCYLA? The most common side effects in people taking KADCYLA for early breast cancer are: Tiredness Nausea Liver problems Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Weakness, numbness, and pain in the hands and feet Joint pain The most common side effects seen in people taking KADCYLA for metastatic breast cancer are: Tiredness Nausea Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Liver problems Constipation Nosebleeds You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. Talk to a healthcare professional for more information about the benefits and risks of KADCYLA. Please see full Prescribing Information for Important Safety Information, including most serious side effects. If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows lymph nodes to which breast cancer can spread, such as those around or near the collarbone, in the armpits, and near the breastbone. Overview This image shows what your treatment plan may look like. Details Diagnosis Neoadjuvant treatment Surgery Adjuvant treatment If SOME cancer cells are present in the tissue removed (known as residual disease), you may start on KADCYLA If NO cancer cells are present in the tissue removed, you do not have residual disease. KADCYLA is not approved for this use, but you may receive other treatment options. Overview This image provides information about neoadjuvant and adjuvant treatment. Details Neoadjuvant treatment (before surgery) One of the goals of neoadjuvant treatment is to help reduce or get rid of cancer cells before surgery. Adjuvant treatment (after surgery) Adjuvant treatment is given with the intent to kill any cancer cells left behind after surgery. Overview This image shows what happened three years after people started the study. Details Three years after people started the study: Eighty-eight percent of the 743 people who received KADCYLA were still cancer free, compared to 77% of the 743 people who received Herceptin The chance of cancer coming back was lowered by 50% for people who received KADCYLA compared to people who received Herceptin At this time of this data review, it was too early in the study to determine if people lived longer with KADCYLA. However, people in the study will continue to be followed and evaluated. This image shows that 1 infusion of KADCYLA is given every 3 weeks for 14 cycles. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows that 1 infusion of KADCYLA is given every 3 weeks. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions.
9720 chars
SUB-PAGE (https://kadcyla.com/safety.html) KADCYLA® (ado-trastuzumab emtansine) Important Safety Information
[H1] KADCYLA Uses and Important Safety Information [H1] Who is KADCYLA for? Early Breast Cancer KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA. Metastatic Breast Cancer KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body. Patients are selected for therapy based on an FDA-approved test for KADCYLA. [H1] Important Safety Information [H2] What is the most Important Safety Information I should know about KADCYLA? Liver problems KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching Heart problems KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness, or irregular heartbeat Pregnancy Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 7 months after your last dose of KADCYLA If you think you may be pregnant, you should contact your healthcare provider immediately If you are exposed to KADCYLA during pregnancy or if you become pregnant within 7 months following your last dose of KADCYLA, you are encouraged to report KADCYLA exposure to Genentech by calling 1-888-835-2555 If you are a male patient with a female partner that could become pregnant, birth control should be used during treatment and for 4 months following your last dose of KADCYLA You should not breastfeed during treatment and for 7 months after the last dose of KADCYLA Contact your doctor right away if you experience symptoms associated with these side effects. [H2] What are the additional possible serious side effects of KADCYLA? Lung problems KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life-threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs Infusion-related reactions Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions Serious bleeding KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood (antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide additional monitoring if you are taking one of these other drugs while on KADCYLA. Even when blood thinners are not also being taken, life-threatening bleeding may occur with KADCYLA Low platelet count Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms Nerve damage Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function. Your doctor will monitor you for symptoms of nerve damage Skin reactions around the infusion site KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion [H2] What are the most common side effects of KADCYLA? The most common side effects in people taking KADCYLA for early breast cancer are: Tiredness Nausea Liver problems Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Weakness, numbness, and pain in the hands and feet Joint pain The most common side effects seen in people taking KADCYLA for metastatic breast cancer are: Tiredness Nausea Pain that affects the bones, muscles, ligaments, and tendons Bleeding Low platelet count Headache Liver problems Constipation Nosebleeds You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. Talk to a healthcare professional for more information about the benefits and risks of KADCYLA. Please see full Prescribing Information for Important Safety Information, including most serious side effects. If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows lymph nodes to which breast cancer can spread, such as those around or near the collarbone, in the armpits, and near the breastbone. Overview This image shows what your treatment plan may look like. Details Diagnosis Neoadjuvant treatment Surgery Adjuvant treatment If SOME cancer cells are present in the tissue removed (known as residual disease), you may start on KADCYLA If NO cancer cells are present in the tissue removed, you do not have residual disease. KADCYLA is not approved for this use, but you may receive other treatment options. Overview This image provides information about neoadjuvant and adjuvant treatment. Details Neoadjuvant treatment (before surgery) One of the goals of neoadjuvant treatment is to help reduce or get rid of cancer cells before surgery. Adjuvant treatment (after surgery) Adjuvant treatment is given with the intent to kill any cancer cells left behind after surgery. Overview This image shows what happened three years after people started the study. Details Three years after people started the study: Eighty-eight percent of the 743 people who received KADCYLA were still cancer free, compared to 77% of the 743 people who received Herceptin The chance of cancer coming back was lowered by 50% for people who received KADCYLA compared to people who received Herceptin At this time of this data review, it was too early in the study to determine if people lived longer with KADCYLA. However, people in the study will continue to be followed and evaluated. This image shows that 1 infusion of KADCYLA is given every 3 weeks for 14 cycles. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions. This image shows a normal cell with a normal amount of HER2, in which cells grow and divide normally; and a HER2+ cancer cell with too much HER2, in which cells grow and divide faster. This image shows that 1 infusion of KADCYLA is given every 3 weeks. This image shows that the first infusion of KADCYLA takes 90 minutes. If prior infusions were well tolerated, all other infusions take 30 minutes. Your healthcare team will wait at least 90 minutes after the first infusion, and at least 30 minutes after each following infusion, to check for any reactions. If side effects occur, they may adjust, delay, or stop your treatment. Wait 3 weeks between infusions.
8777 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
8Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 0 |
| /early-breast-cancer.html | 2 | 0 |
| /metastatic-breast-cancer.html | 2 | 0 |
| /safety.html | 2 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
}
/early-breast-cancer.html
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
}
/metastatic-breast-cancer.html
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
}
/safety.html
{
"@context": "http://schema.org",
"@type": "Organization",
"name": "Genentech",
"url": "https://www.gene.com/",
"logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
"description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
"contactPoint": {
"@type": "ContactPoint",
"telephone": "+1-877-436-3683",
"contactType": "customer service"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "1 DNA Way",
"addressLocality": "South San Francisco",
"addressRegion": "California",
"postalCode": "94080",
"addressCountry": "US"
}
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
✓ Less BS than average
Genentech has 25.7 points less BS than the average for Medical Devices, Pharma & Biotech.
BS Detector
Medical Devices, Pharma & Biotech BS: Genentech (kadcyla.com)
https://kadcyla.com
📍 Industry: Medical Devices, Pharma & Biotech
15
BS / 100
Kadcyla.com is a fortress of legal compliance and clinical rigidity, where substance significantly outweighs signal. The site suffers from the typical ‘pharma-template’ malaise, but the density of actual trial data makes it nearly immune to traditional BS. Its only ‘bullshit’ is the mechanical repetition of marketing slogans required to make toxic chemotherapy sound like a ‘journey’.
Info Density
Power-words vs. Substance ratio.
3
10% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
8
40% BS
Commodity Fingerprint
Detection of industry clichés/templates.
4
27% BS
Identity & Authority
Expert verifiability & Schema depth.
0
0% BS
Add specific ClinicalTrials.gov registration numbers (NCT identifiers) directly beneath the three-year trial outcome images to move from ‘trust theatre’ to forensic validation. Differentiate the H1 headings on the indication sub-pages; using the same ‘2 cancer-fighting agents’ slogan on both Early and Metastatic pages creates a commodity template feel. Integrate outbound links to the peer-reviewed publications for the KATHERINE and EMILIA trials to provide a verification path for the claimed success rates. Address the backend metadata discrepancy where a review_count is flagged without associated proof links to eliminate technical trust theatre signals.
The content perfectly aligns with the Pharma & Biotech category, specifically focusing on oncology treatment for HER2-positive breast cancer. The presence of extensive Safety Information and clinical trial results confirms its classification as a highly regulated medical drug site.
“The low score of 15 reflects the high regulatory burden of pharmaceutical sites, which mandates substance (Safety Information, trial percentages, and specific dosing timelines). Points were only lost for the repetition of the '2-in-1' value proposition across indication pages and a trust theatre flag triggered by the presence of a review count without verified proof links in the metadata. The identity and authority of Genentech are fully supported by robust Organization schema and FDA-compliant disclosures.”
Verified Analysis Date: May 31, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Genentech, captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Genentech: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://kadcyla.com to view the most current version of its content and learn from the source what this company is about and what it offers.